MS-SMART (Multiple
Sclerosis-Secondary Progressive Multi-Arm Randomisation
Trial)
February 2016
Hi there!
Following Dr Chataway’s previous post on this
blog, we wanted to inform you that recruitment is still ongoing for the
MS-SMART trial and will end April 2016.
MS-SMART is a phase 2 clinical trial looking at
disease progression in people with secondary progressive MS (SPMS). The study
involves testing one of three different drugs (amiloride, riluzole and
fluoxetine) against a placebo (dummy drug) to see if they can slow down the
worsening of disability. As you are aware, this trial is important as there is
currently no treatment for progression in MS.
You can read more about MS-SMART on our website:
The trial inclusion criteria include:
-Diagnosis of
SPMS
-Steady
progression of clinical disability in the preceding 2 years
-Still able to
walk at least 20 metres with bilateral support (EDSS: 4.0-6.5)
-Aged 25 to 65
(inclusive)
-Able to
undertake MRI
-Not on certain
medications including: MS disease modifying therapy, fluoxetine, citalopram,
escitalopram, and sertraline
So far, at all
of the UK MS SMART recruiting sites, we have almost reached our participant
target, and are getting in touch to see if anyone would be happy to attend our centre
where we can offer you an appointment soon to check whether you might be
eligible. We are based at the main MS-SMART site at UCL, Institute of
Neurology, Queen Square, London.
Working
together we can meet our target. If you are interested in taking part, please
contact us via:
Email: domenico.plantone@nhs.net
Or call:
07572898453
Thank you in
advance,
Dr Domenico
Plantone
On behalf of Dr Jeremy Chataway and the MS SMART team